Form 4: Corcept CFO Atabak Mokari Reports Stock Transactions

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, reported recent stock acquisitions and tax-related dispositions of company common stock.

Summary

• Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc. (CORT), reported transactions involving the company's common stock.
• On September 2, 2025, Mokari purchased 200 shares of common stock at a price of $71.38 per share under a purchase plan established by the 2024 Incentive Award Plan.
• Also on September 2, 2025, Mokari was granted 200 unvested restricted stock awards (RSAs) under the Purchase Plan, with a price of $0.00, which will vest on the one-year anniversary of the grant date provided the Purchase Plan Shares are retained.
• On September 3, 2025, 144 shares were withheld by the Issuer to satisfy tax withholding obligations related to the vesting of restricted stock units, calculated at a closing price of $71.38 per share.
• Following these transactions, Mokari beneficially owns 14,321 shares of common stock, which includes 1,238 shares underlying previously granted unvested restricted stock awards from December 2, 2024, March 3, 2025, and June 2, 2025, plus the newly granted 200 unvested RSAs.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the insider purchase of shares, indicating management confidence. This is balanced by the routine nature of the tax-related disposition and the relatively small transaction size, making it a neutral to slightly positive event.

Positives

• The Chief Financial Officer's purchase of 200 shares at market price may signal management's confidence in the company's valuation and future prospects.

Negatives

• The disposition of 144 shares was for tax withholding purposes, which is a routine event and not indicative of a negative outlook.

Future Outlook

The filing indicates that certain restricted stock awards will vest on their one-year anniversary of the grant date, contingent on the Reporting Person satisfying specific requirements or remaining the beneficial owner of the Purchase Plan Shares.

Industry Context

This Form 4 filing details routine insider transactions, which are common in publicly traded companies. Such filings provide transparency regarding management's equity holdings and trading activities, offering a glimpse into their confidence in the company's stock.

Stakeholder Impact

• Shareholders may view the Chief Financial Officer's purchase of company stock as a positive signal of management's belief in the company's future performance and value.

Next Steps

• Vesting of 231 restricted stock awards on December 2, 2025 (one-year anniversary of grant date).
• Vesting of 232 restricted stock awards on March 3, 2026 (one-year anniversary of grant date).
• Vesting of 775 restricted stock awards on June 2, 2026 (one-year anniversary of grant date).
• Vesting of 200 restricted stock awards on September 2, 2026 (one-year anniversary of grant date), contingent on retaining Purchase Plan Shares.

Key Dates

Recommendation

The filing details routine insider transactions, including a purchase and a tax-related disposition. While the insider purchase is a minor positive signal, the transaction volume is not substantial enough to warrant a strong buy or sell recommendation. Investors should consider this information as a data point within a broader investment thesis, maintaining a 'hold' position based solely on this filing.

Keywords

Corcept Therapeutics, CORT, Atabak Mokari, Insider Trading, Form 4, Stock Purchase, Restricted Stock Awards, CFO